Resting Heart Rate and Cardiovascular Disease: The Beta-Blocker-Hypertension Paradox

Journal of the American College of Cardiology

Volumn 51, Issue 3, 2008, Pages 330-331

  Messerli, Franz H ^a   Bangalore, Sripal ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; LETTER; MORTALITY; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; BRADYCARDIA; CARDIOVASCULAR DISEASES; HEART RATE; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 38149072440     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.09.040     Document Type: Letter

References (4)

1. Fox K., Borer J.S., Camm A.J., et al., Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50 (2007) 823-830
2. Bangalore S., Sawhney S., Uretsky S., and Messerli F.H. Heart rate and anti-hypertensive therapy-Kjekshus hypothesis revisited. (abstr). Circulation 116 (2007) II654
3. Williams B., Lacy P.S., Thom S.M., et al., CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 (2006) 1213-1225
4. Messerli F.H., Williams B., and Ritz E. Essential hypertension. Lancet 370 (2007) 591-603